190 related articles for article (PubMed ID: 8383653)
1. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
Acar JF; Goldstein FW; Kitzis MD
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
[TBL] [Abstract][Full Text] [Related]
2. Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles.
Chen HY; Bonfiglio G; Allen M; Piper D; Edwardson T; McVey D; Livermore DM
J Antimicrob Chemother; 1993 Aug; 32(2):247-66. PubMed ID: 8226427
[TBL] [Abstract][Full Text] [Related]
3. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
[TBL] [Abstract][Full Text] [Related]
4. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
6. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
Reeves DS; Holt HA; Bywater MJ; MacGowan AP
J Antimicrob Chemother; 1993 Jul; 32(1):51-61. PubMed ID: 8226417
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.
Livermore DM; Mushtaq S; James D; Potz N; Walker RA; Charlett A; Warburton F; Johnson AP; Warner M; Henwood CJ
Int J Antimicrob Agents; 2003 Jul; 22(1):14-27. PubMed ID: 12842324
[TBL] [Abstract][Full Text] [Related]
9. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
Johnson DM; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
Birawska I; Fuchs J; Szulakowska E
Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
Chang SC; Hsu LY; Luh KT; Hsieh WC
J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
Fass RJ; Prior RB
Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
[TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
Cormican M; Corbett-Feeney G; Kelly S; Hughes D; Flynn J; Jones RN
Ir J Med Sci; 1998; 167(3):155-9. PubMed ID: 9780564
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
Pfaller MA; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC
Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):728-32. PubMed ID: 1330566
[TBL] [Abstract][Full Text] [Related]
17. [Second multicenter study of the in vitro susceptibility to piperacillin-tazobactam].
García-Rodríguez JA; Trujillano I;
Rev Esp Quimioter; 2002 Jun; 15(2):169-75. PubMed ID: 12582446
[TBL] [Abstract][Full Text] [Related]
18. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.
Baron EJ; Jones RN
Diagn Microbiol Infect Dis; 1995 Mar; 21(3):141-51. PubMed ID: 7648835
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients.
Mokaddas E; Rotimi VO; Sanyal SC
J Chemother; 1998 Jun; 10(3):208-14. PubMed ID: 9669645
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
Qadri SM; Ueno Y; Cunha BA
Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
